MATHIAS OELKE - 05 Apr 2022 Form 3 Insider Report for NexImmune, Inc.

Role
Chief Science Officer
Signature
/s/ Ilse Johnson, Attorney-in-fact
Issuer symbol
NEXI on OTC
Transactions as of
05 Apr 2022
Net transactions value
$0
Form type
3
Filing time
07 Apr 2022, 19:10:47 UTC
Next filing
25 Nov 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding NEXI Common Stock 7,923 05 Apr 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding NEXI Stock Option (Right to Buy) 05 Apr 2022 Common Stock 15,793 $2.42 Direct F1
holding NEXI Stock Option (Right to Buy) 05 Apr 2022 Common Stock 47,379 $2.42 Direct F1
holding NEXI Stock Option (Right to Buy) 05 Apr 2022 Common Stock 4,755 $2.58 Direct F1
holding NEXI Stock Option (Right to Buy) 05 Apr 2022 Common Stock 115,051 $2.58 Direct F1
holding NEXI Stock Option (Right to Buy) 05 Apr 2022 Common Stock 31,948 $4.31 Direct F1
holding NEXI Stock Option (Right to Buy) 05 Apr 2022 Common Stock 19,905 $17.00 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 All shares underlying this option have vested.
F2 25% of this option vested and became exercisable on February 11, 2022, with the remainder vesting in 36 equal monthly installments thereafter.

Remarks:

Exhibit 24.1 - Power of Attorney